19th Ave New York, NY 95822, USA
Join Now

Grup de Tumors del Tracte Gastrointestinal

Portfolio Item Grup de Tumors del Tracte Gastrointestinal
RECERCA CLÍNICA

El Grup de Tumors del Tracte Gastrointestinal, liderat per Elena Élez, compta amb una àmplia experiència en el maneig d’aquesta malaltia. Liderem i coliderem diversos projectes de recerca clínica i traslacional orientats a identificar nous biomarcadors pronòstics i predictius que ajudin a guiar la presa de decisions terapèutiques i a desxifrar els mecanismes de resistència als fàrmacs en el càncer colorectal (CCR).

El nostre grup està reconegut com a referent en la recerca del CCR mutat en BRAF. Aquesta mutació s’associa a característiques clinicopatològiques i moleculars agressives, incloent-hi la diferenciació mucinosa i la inestabilitat de microsatèl·lits. Com a exemple dels nostres esforços en aquest àmbit, els nostres investigadors van participar en l’estudi pivotal de fase III BEACON, que va conduir a l’aprovació de l’inhibidor de BRAF encorafenib en combinació amb cetuximab per al tractament de pacients amb CCR BRAFV600E mutat. A més, hem ampliat la nostra cohort de pacients amb CCR mutat en BRAF mitjançant un assaig d’iniciativa pròpia que avalua l’eficàcia d’una nova combinació de fàrmacs —encorafenib, cetuximab i bevacizumab— en aquest context.

També liderem i participem activament en altres estudis clínics rellevants destinats a ampliar les estratègies terapèutiques efectives contra el CCR metastàtic, incloent-hi combinacions basades en immunoteràpia. Els nostres esforços en desenvolupament de fàrmacs han contribuït a l’aprovació de diversos tractaments dirigits, entre ells trifluridina-tipiracil més bevacizumab en mCCR refractari, pembrolizumab en CCR avançat MSI-H i fruquintinib en mCCR refractari.

Una línia de recerca clau que pretenem consolidar en els propers anys està centrada en el CCR d’inici precoç (EO-CRC). L’augment global de la seva incidència en persones joves (< 50 anys) continua sent una preocupació urgent. Encara que les causes d’aquesta tendència alarmant no es coneixen completament, és probable que hi hagi una associació amb les exposicions ambientals acumulades al llarg de la vida (exposoma), que provoquen alteracions genètiques i epigenètiques en les cèl·lules epitelials colorectals, la microbiota intestinal i la immunitat de l’hoste. El nostre objectiu és descobrir els mecanismes implicats en la patogènesi del CCR en pacients joves i investigar la interacció dels diversos factors que l’impulsen.

La microbiota ha demostrat tenir un paper fonamental en el metabolisme, l’eficàcia i la toxicitat dels fàrmacs, així com en el desenvolupament del càncer. Els nostres estudis en aquest camp es basen en col·laboracions multidisciplinàries i en nous enfocaments per integrar l’anàlisi de diverses mostres biològiques (femtes i saliva), juntament amb sistemes experimentals sofisticats per avaluar-ne la funcionalitat.

Considerant l’evidència creixent que demostra la importància de les interaccions nutrició-microbioma en càncer, hem dissenyat un qüestionari de freqüència alimentària (CFA) per estudiar els patrons dietètics de la població espanyola i el seu impacte en la microbiota intestinal. La validesa del qüestionari s’avaluarà comparant la ingesta d’aliments i nutrients reportada pels pacients amb registres d’alimentació de tres dies en individus sans. A més, s’analitzarà la reproductibilitat del CFA en pacients diagnosticats de càncer de còlon a l’Hospital Universitari Vall d’Hebron.

Així mateix, estem desenvolupant projectes específics en càncer de recte. Centrant-nos principalment en estadis localitzats, aquests esforços busquen optimitzar el tractament perioperatori i la cirurgia. Sota el lideratge de Jaume Capdevila, s’han desenvolupat assaigs clínics per a aquesta població de pacients, incloent-hi l’estudi DUREC, dissenyat per avaluar l’addició d’immunoteràpia (durvalumab) a la quimioradioteràpia estàndard amb la finalitat d’augmentar la probabilitat de curació.

Els esforços traslacionals en càncer de recte també inclouen l’anàlisi de la microbiota i el seu impacte en l’eficàcia del tractament. Entre altres estudis en marxa, ens centrem a investigar la microbiota i la seva associació amb el desenvolupament del càncer de recte i la resposta al tractament, i liderem l’estudi TAU-TEM en malaltia en estadi primerenc, fomentant la col·laboració amb altres disciplines, com la cirurgia i la radioteràpia.

Elena Élez
Cap de grup
Biosketch

Liníes de recerca

  • Contribuir al desenvolupament de fàrmacs en càncer colorectal (CCR) mitjançant la nostra participació en assaigs clínics internacionals innovadors i òptimament dissenyats.
  • Estudiar els mecanismes de resistència a fàrmacs en CCR mutat en BRAF.
  • Identificar nous biomarcadors predictius de resposta al tractament.
  • Investigar el CCR d’inici precoç. Identificar i comprendre els mecanismes implicats, amb especial èmfasi en l’impacte del microbioma.
  • Desenvolupar i implementar nous enfocaments diagnòstics i models de tumor-en-un-xip per estudiar el microambient tumoral del CCR.
  • Caracteritzar el potencial del microbioma intestinal com a determinant de la resposta o resistència al tractament i avaluar-ne la viabilitat terapèutica en CCR.
  • Validar i avaluar la reproductibilitat del qüestionari de freqüència d’aliments per estudiar els patrons dietètics de la població espanyola i el seu impacte en la microbiota intestinal.
  • Estudiar les metàstasis hepàtiques del càncer colorectal des de diferents perspectives per aprofundir en la comprensió del seu patró de creixement i el seu paper com a factor pronòstic.

Equip

Cap de grup
Elena Élez
Equipo de Cáncer de Colon: Oncólogos médicos e investigadores clínicos
Iosune Baraibar
Francesc Salvà
Nadia Saoudí
Francisco Javier Ros
Marta Rodríguez
Infermera de Recerca oncològica
Ariadna Garcia
Research coordinator
Sebastián Guzmán
Colon Taskforce Manager
Mireia Sanchís
Nutricionista
Adriana Alcaraz
Equip de Càncer de Recte: Oncòleg mèdic i consultor sènior
Jaume Capdevila
Metges oncòlegs
Jorge Hernando
Alejandro Garcia
Infermera de Recerca oncològica
Ana Vazquez
Gestora de mostres
Inés Suárez

Projectes

Ampliando el beneficio de la inmunoterapia en cáncer colorrectal metastásico con estabilidad de microsatélites mediante radiómica y biomarcadores circulantes. Entidad financiadora: Fundación SEOM. PI: Iosune Baraibar

Título: Biomarker indentification in patients with BRAF mutant metastatic colorectal cancer to guide treatment strategy and overcome primary/adquired restances to BRAF Inhibior-targeted agents (BRAFsistance). Entidad Financiadora: Fundación CRIS. Periodo de Ejecución: 1/05/2024-30/04/2029. PI: Elena Élez

Título:  Evaluación de las estructuras linfoides terciarias (TLS) como biomarcador en el cáncer colorrectal metastásico tratado con combinaciones de puntos de control inmunitarios. Entidad Financiadora: Fundación SEOM. Periodo de Ejecución: 1/12/2023-30/11/2025. PI: María Elena Élez

Título: Uso de estreptozotocina en pacientes con tumores neuroendocrinos bien diferenciados: datos de la vida real y comparación con esquemas de quimioterapia basados en temozolomida. Entidad Financiadora: Grupo Español de Tumores Neuroendorinos y Endocrinos (GETNE). Periodo de Ejecución: 01/01/2024-31/12/2024. PI: Alejandro García

Título: Eficacia de las diferentes secuencias de tratamiento con inhibidores multikinasa en pacientes con carcinoma diferenciado de tiroides en el registro regetne-tiroides. Entidad Financiadora: Grupo Español de Tumores Neuroendorinos y Endocrinos (GETNE). Periodo de Ejecución: 01/01/2024-31/12/2024. PI: Alejandro García

Publicacions

Publicacions científiques més rellevants

  1. Dasari A, Lonardi S, Garcia-Carbonero R, Elez E, Yoshino T, Sobrero A, Yao J, García-Alfonso P, Kocsis J, Cubillo Gracian A, Sartore-Bianchi A, Satoh T, Randrian V, Tomasek J, Chong G, Paulson AS, Masuishi T, Jones J, Csőszi T, Cremolini C, Ghiringhelli F, Shergill A, Hochster HS, Krauss J, Bassam A, Ducreux M, Elme A, Faugeras L, Kasper S, Van Cutsem E, Arnold D, Nanda S, Yang Z, Schelman WR, Kania M, Tabernero J, Eng C; FRESCO-2 Study Investigators. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet. 2023 Jul 1;402(10395):41-53.
  2. Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, Cruz FM, Wyrwicz L, Stroyakovskiy D, Pápai Z, Poureau PG, Liposits G, Cremolini C, Bondarenko I, Modest DP, Benhadji KA, Amellal N, Leger C, Vidot L, Tabernero J; SUNLIGHT Investigators. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer. N Engl J Med. 2023 May 4;388(18):1657-1667.
  3. Strickler JH, Cercek A, Siena S, André T, Ng K, Van Cutsem E, Wu C, Paulson AS, Hubbard JM, Coveler AL, Fountzilas C, Kardosh A, Kasi PM, Lenz HJ, Ciombor KK, Elez E, Bajor DL, Cremolini C, Sanchez F, Stecher M, Feng W, Bekaii-Saab TS; MOUNTAINEER investigators. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 2023 May;24(5):496-508.
  4. Ros J, Matito J, Villacampa G, Comas R, Garcia A, Martini G, Baraibar I, Saoudi N, Salvà F, Martin Á, Antista M, Toledo R, Martinelli E, Pietrantonio F, Boccaccino A, Cremolini C, Dientsmann R, Tabernero J, Vivancos A, Elez E. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments. Ann Oncol. 2023 Jun;34(6):543-552.

 

Totes les publicacions

  1. Andre T, Elez E, Van Cutsem E, Jensen LH, Bennouna J, Mendez G, Schenker M, de la Fouchardiere C, Limon ML, Yoshino T, Li J, Lenz HJ, Manzano Mozo JL, Tortora G, Garcia-Carbonero R, Dahan L, Chalabi M, Joshi R, Goekkurt E, Braghiroli MI, Cil T, Cela E, Chen T, Lei M, Dixon M, Abdullaev S, Lonardi S; CheckMate 8HW Investigators. Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer. N Engl J Med. 2024 Nov 28;391(21):2014-2026. doi: 10.1056/NEJMoa2402141.
  2. Ambrosini M, Rousseau B, Manca P, Artz O, Marabelle A, André T, Maddalena G, Mazzoli G, Intini R, Cohen R, Cercek A, Segal NH, Saltz L, Varghese AM, Yaeger R, Nusrat M, Goldberg Z, Ku GY, El Dika I, Margalit O, Grinshpun A, Murtaza Kasi P, Schilsky R, Lutfi A, Shacham-Shmueli E, Khan Afghan M, Weiss L, Westphalen CB, Conca V, Decker B, Randon G, Elez E, Fakih M, Schrock AB, Cremolini C, Jayachandran P, Overman MJ, Lonardi S, Pietrantonio F. Immune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer. Ann Oncol. 2024 Jul;35(7):643-655. doi: 10.1016/j.annonc.2024.03.009.
  3. Kawazoe A, Xu RH, García-Alfonso P, Passhak M, Teng HW, Shergill A, Gumus M, Qvortrup C, Stintzing S, Towns K, Kim TW, Shiu KK, Cundom J, Ananda S, Lebedinets A, Fu R, Jain R, Adelberg D, Heinemann V, Yoshino T, Elez E; LEAP-017 Investigators. Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study. J Clin Oncol. 2024 Aug 20;42(24):2918-2927. doi: 10.1200/JCO.23.02736.
  4. Siena S, Raghav K, Masuishi T, Yamaguchi K, Nishina T, Elez E, Rodriguez J, Chau I, Di Bartolomeo M, Kawakami H, Suto F, Koga M, Inaki K, Kuwahara Y, Takehara I, Barrios D, Kobayashi K, Grothey A, Yoshino T. HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01. Nat Commun. 2024 Nov 25;15(1):10213. doi: 10.1038/s41467-024-53223-3. Erratum in: Nat Commun. 2025 Jan 15;16(1):704. doi: 10.1038/s41467-025-56170-9.
  5. Lenz HJ, Parikh A, Spigel DR, Cohn AL, Yoshino T, Kochenderfer M, Elez E, Shao SH, Deming D, Holdridge R, Larson T, Chen E, Mahipal A, Ucar A, Cullen D, Baskin-Bey E, Kang T, Hammell AB, Yao J, Tabernero J. Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial. J Immunother Cancer. 2024 Mar 13;12(3):e008409. doi: 10.1136/jitc-2023-008409.
  6. Randon G, Nakamura Y, Yaeger R, Lonardi S, Cremolini C, Elez E, Nichetti F, Ghelardi F, Nasca V, Bergamo F, Conca V, Ros J, Bando H, Maddalena G, Oldani S, Prisciandaro M, Raimondi A, Schrock AB, Agnelli L, Walch H, Yoshino T, Pietrantonio F. Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study. Clin Cancer Res. 2024 Jan 17;30(2):436-443. doi: 10.1158/1078-0432.CCR-23-1379.
  7. Martínez-Quintanilla J, Cabot D, Sabia D, Arqués O; PMPnet Group; Vergés J, Chicote I, Bijelic L; PMPnet Group; Cabellos L, Alcántara AM, Ramos I, Barrios P, Crusellas O, Palacio LM; PMPnet Group; Cámara JA, Barriuso J; PMPnet Group; Jiménez JJ, Muñoz-Torres P, Nonell L, Flores R, Médico E, Guaglio M; PMPnet Group; Ros J, Élez E, Tabernero J, Aziz O, Deraco M, Palmer HG; PMPnet Group; PMPnet Group. Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma Peritonei. Clin Cancer Res. 2024 Sep 13;30(18):4082-4099. doi: 10.1158/1078-0432.CCR-23-4072.
  8. Mirandola A, Kudriavtsev A, Cofre Muñoz CI, Navarro RC, Macagno M, Daoud S, Sanchez C, Pastor B, Pisareva E, Marin MS, Ruiz JG, Piris A, Rodriguez AG, Gonzalez NS, Vivancos A, Quarà V, Mellano A, Borghi F, Corti G, Marchiò C, Sapino A, Bartolini A, Crisafulli G, Bardelli A, Di Maio M, Lossaint G, Frayssinoux F, Crapez E, Ychou M, Soler RS, Fenocchio E, Fernandez Calotti PX, Mazard T, Vivas CS, Elez E, Di Nicolantonio F, Thierry AR. Post-surgery sequelae unrelated to disease progression and chemotherapy revealed in follow-up of patients with stage III colon cancer. EBioMedicine. 2024 Oct;108:105352. doi: 10.1016/j.ebiom.2024.105352.
  9. Ambrosini M, Tougeron D, Modest D, Guimbaud R, Kopetz S, Decraecker M, Kim S, Coutzac C, Perkins G, Alouani E, Marmorino F, Pernot S, Sinicrope FA, Elez E, Parent P, Cremolini C, Pietrantonio F, Lonardi S, Gallois C, Taieb J. BRAF + EGFR +/- MEK inhibitors after immune checkpoint inhibitors in BRAF V600E mutated and deficient mismatch repair or microsatellite instability high metastatic colorectal cancer. Eur J Cancer. 2024 Oct;210:114290. doi: 10.1016/j.ejca.2024.114290.
  10. Janku F, Kim TM, Iyer G, Spreafico A, Elez E, de Jonge M, Yamamoto N, van der Wekken AJ, Ascierto PA, Maur M, Marmé F, Kiladjian JJ, Basu S, Baffert F, Buigues A, Chen C, Cooke V, Giorgetti E, Kim J, McCarthy F, Moschetta M, Dummer R. First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations. Eur J Cancer. 2024 Jan;196:113458. doi: 10.1016/j.ejca.2023.113458.
  11. García-Alfonso P, Elez E, Soto-Alsar J, Páez D, Fernández-Montes A, Graña B, Salud A, Yubero A, Gómez-España MA, Macías I, Quintero G, López-López C, Fernández-Rodríguez T, Grávalos C, González-Flores E, Guix M, García Paredes B, Reina JJ, Rodríguez Mowbray JR, Sastre J, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Maintenance with 5-FU/LV-aflibercept after induction with FOLFIRI-aflibercept versus FOLFIRI-aflibercept until progression as second-line treatment in older adults with metastatic colorectal cancer: the AFEMA phase II randomized trial. ESMO Open. 2024 Dec;9(12):103986. doi: 10.1016/j.esmoop.2024.103986.
  12. Segal NH, Tie J, Kopetz S, Ducreux M, Chen E, Dienstmann R, Hollebecque A, Reilley MJ, Elez E, Cosaert J, Cain J, Soo-Hoo Y, Hewson N, Cooper ZA, Kumar R, Tabernero J. COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer. Br J Cancer. 2024 Oct;131(6):1005-1013. doi: 10.1038/s41416-024-02796-3.
  13. Elez E, Cubillo A, Alfonso PG, Middleton MR, Chau I, Alkuzweny B, Alcasid A, Zhang X, Van Cutsem E. Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study. BMC Cancer. 2024 Apr 11;24(1):446. doi: 10.1186/s12885-024-12153-5.
  14. Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Élez E, Wyrwicz L, Stroyakovskiy D, Liposits G, Bondarenko I, Modest DP, Amellal N, Tabernero J; SUNLIGHT Investigators. Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer. Future Oncol. 2024;20(36):2823-2832. doi: 10.1080/14796694.2024.2366100.
  15. Elez E, Kopetz S, Tabernero J, Bekaii-Saab T, Taieb J, Yoshino T, Manji G, Fernandez K, Abbattista A, Zhang X, Morris VK. SEAMARK: phase II study of first-line encorafenib and cetuximab plus pembrolizumab for MSI-H/dMMR BRAFV600E-mutant mCRC. Future Oncol. 2024 Apr;20(11):653-663. doi: 10.2217/fon-2022-1249.
  16. García-Alfonso P, Vera R, Aranda E, Élez E, Rivera F. Delphi consensus for the third-line treatment of metastatic colorectal cancer. Clin Transl Oncol. 2024 Jun;26(6):1429-1437. doi: 10.1007/s12094-023-03369-1.
  17. Salvà F, Saoudi N, Rodríguez M, Baraibar I, Ros J, García A, Tabernero J, Elez E. Determinants of Metastatic Colorectal Cancer With Permanent Liver- Limited Disease. Clin Colorectal Cancer. 2024 Sep;23(3):207-214. doi: 10.1016/j.clcc.2024.05.010.
  18. Ros J, Vaghi C, Baraibar I, Saoudi González N, Rodríguez-Castells M, García A, Alcaraz A, Salva F, Tabernero J, Elez E. Targeting KRASG12C Mutation in Colorectal Cancer, A Review: New Arrows in the Quiver. Int J Mol Sci. 2024 Mar 14;25(6):3304. doi: 10.3390/ijms25063304.
  19. Salva de Torres C, Baraibar I, Saoudi González N, Ros J, Salva F, Rodríguez-Castells M, Alcaraz A, García A, Tabernero J, Élez E. Current and Emerging Treatment Paradigms in Colorectal Cancer: Integrating Hallmarks of Cancer. Int J Mol Sci. 2024 Jun 26;25(13):6967. doi: 10.3390/ijms25136967.
  20. Saoudi González N, Ros J, Baraibar I, Salvà F, Rodríguez-Castells M, Alcaraz A, García A, Tabernero J, Élez E. Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer. Cancers (Basel). 2024 Jan 18;16(2):412. doi: 10.3390/cancers16020412.
  21. González NS, Marchese PV, Baraibar I, Ros J, Salvà F, Rodríguez M, Salvà C, Vaghi C, Alcaraz A, García A, Tabernero J, Élez E. Epidermal growth factor receptor antagonists in colorectal cancer: emerging strategies for precision therapy. Expert Opin Investig Drugs. 2024 Jun;33(6):613-625. doi: 10.1080/13543784.2024.2349287.
  22. Contreras-Toledo D, Jiménez-Fonseca P, López CL, Montes AF, López Muñoz AM, Vázquez Rivera F, Alonso V, Alcaide J, Salvà F, Covela Rúa M, Guillot M, Martín Carnicero A, Jimeno Mate R, Cameselle García S, Asensio Martínez E, González Astorga B, Fernandez-Diaz AB, González Villaroel P, Virgili Manrique AC, Melián Sosa M, Alonso B, Cousillas Castiñeiras A, Castañón López C, Aparicio J, Carmona-Bayonas A. Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist? Br J Cancer. 2024 Mar;130(5):777-787. doi: 10.1038/s41416-023-02563-w.
  23. Genova C, Marconi S, Chiorino G, Guana F, Ostano P, Santamaria S, Rossi G, Vanni I, Longo L, Tagliamento M, Zullo L, Dal Bello MG, Dellepiane C, Alama A, Rijavec E, Ludovini V, Barletta G, Passiglia F, Metro G, Baglivo S, Chiari R, Rivoltini L, Biello F, Baraibar I, Gil-Bazo I, Novello S, Grossi F, Coco S. Extracellular vesicles miR-574-5p and miR-181a-5p as prognostic markers in NSCLC patients treated with nivolumab. Clin Exp Med. 2024 Aug 6;24(1):182. doi: 10.1007/s10238-024-01427-8.
  24. Cabrero-de Las Heras S, Hernández-Yagüe X, González A, Losa F, Soler G, Bugés C, Baraibar I, Esteve A, Pardo-Cea MÁ, Ree AH, Martínez-Bosch N, Nieva M, Musulén E, Meltzer S, Lobato T, Vendrell-Ayats C, Queralt C, Navarro P, Montagut C, Grau-Leal F, Camacho D, Legido R, Mulet-Margalef N, Martínez-Balibrea E. Changes In Serum CXCL13 Levels Are Associated With Outcomes of Colorectal Cancer Patients Undergoing First-Line Oxaliplatin-Based Treatment. Biomed Pharmacother. 2024 Jul;176:116857. doi: 10.1016/j.biopha.2024.116857.
  25. Ros J, Matito J, Villacampa G, Comas R, Garcia A, Martini G, Baraibar I, Saoudi N, Salvà F, Martin Á, Antista M, Toledo R, Martinelli E, Pietrantonio F, Boccaccino A, Cremolini C, Dienstmann R, Tabernero J, Vivancos A, Elez E. Corrigendum to “Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments”: [Annals of Oncology 34 (2023) 543-552]. Ann Oncol. 2024 Oct;35(10):922. doi: 10.1016/j.annonc.2023.07.010. Epub 2024 Aug 12. Erratum for: Ann Oncol. 2023 Jun;34(6):543-552.
  26. García-Alfonso P, Jimenez-Fonseca P, Soto-Alsar J, Baraibar I, Santos C, La Casta A, Ghanem I, Pulido Cortijo G, Mariño Méndez A, Pazo-Cid R, Vera R, Melián M, Alcaide J, Graña B, Páez D, Gallego I, Lobo M, Borregón M, Fernández Montes A, Martínez de Castro E, Carmona-Bayonas A, Aranda E. Three-year survival follow-up of patients with gastrointestinal cancer treated during the COVID-19 pandemic in Spain: data from the PANDORA-TTD20 study. Oncologist. 2024 Nov 16:oyae300. doi: 10.1093/oncolo/oyae300.
  27. Ros J, Ucha JM, Garcia-Galea E, Gomez P, Martini G, Balconi F, Comas R, Alonso V, Rodriguez M, Baraibar I, Salva F, Saoudi N, Alcaraz A, Garcia A, Tabernero J, Elez E. Real-World Data of Patients with BRAFV600E-Mutated Metastatic Colorectal Cancer Treated with Trifluridine/Tipiracil. Cancers (Basel). 2024 Dec 12;16(24):4140. doi: 10.3390/cancers16244140.
  28. Fruquintinib versus placebo in patients with refractory metastatic colorectal  cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase  3 study..Dasari, Arvind ; Lonardi, Sara ; Garcia-Carbonero, Rocio ; ELEZ FERNANDEZ, MARIA ELENA; Yoshino, Takayuki ; Sobrero, Alberto ; Yao, James ; García-Alfonso, Pilar ; Kocsis, Judit ; Cubillo Gracian, Antonio ; Sartore-Bianchi, Andrea ; Satoh, Taroh ; Randrian, Violaine ; Tomasek, Jiri ; Chong, Geoff ; Paulson, Andrew Scott ; Masuishi, Toshiki ; Jones, Jeremy ; Csoszi, Tibor ; Cremolini, Chiara ; Ghiringhelli, Francois ; Shergill, Ardaman ; Hochster, Howard S ; Krauss, John ; Bassam, Ali ; Ducreux, Michel ; Elme, Anneli ; Faugeras, Laurence ; Kasper, Stefan ; Van Cutsem, Eric ; Arnold, Dirk ; Nanda, Shivani ; Yang, Zhao ; Schelman, William R ; Kania, Marek ; TABERNERO CATURLA, JOSEP; Eng, Cathy ; FRESCO-2 Study Investigators.LANCET.1.1.168,9.13.10.1016/S0140-6736(23)00772-9
  29. Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer..Hadoux, Julien ; Elisei, Rossella ; Brose, Marcia S ; Hoff, Ana O ; Robinson, Bruce G ; Gao, Ming ; Jarzab, Barbara ; Isaev, Pavel ; Kopeckova, Katerina ; Wadsley, Jonathan ; Führer, Dagmar ; Keam, Bhumsuk ; Bardet, Stéphane ; Sherman, Eric J ; Tahara, Makoto ; Hu, Mimi I ; Singh, Ravinder ; Lin, Yan ; Soldatenkova, Victoria ; Wright, Jennifer ; Lin, Boris ; Maeda, Patricia ; CAPDEVILA CASTILLON, JAUME; Wirth, Lori J ; LIBRETTO-531 Trial Investigators.NEW ENGLAND JOURNAL OF MEDICINE.1.1.158,5.7.10.1056/NEJMoa2309719
  30. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal  Cancer..Prager, Gerald W ; Taieb, Julien ; Fakih, Marwan ; Ciardiello, Fortunato ; Van Cutsem, Eric ; ELEZ FERNANDEZ, MARIA ELENA; Cruz, Felipe M ; Wyrwicz, Lucjan ; Stroyakovskiy, Daniil ; Pápai, Zsuzsanna ; Poureau, Pierre-Guillaume ; Liposits, Gabor ; Cremolini, Chiara ; Bondarenko, Igor ; Modest, Dominik P ; Benhadji, Karim A ; Amellal, Nadia ; Leger, Catherine ; Vidot, Loïck ; TABERNERO CATURLA, JOSEP; SUNLIGHT Investigators ; Amann, Arno ; Gerger, Armin ; Greil, Richard ; Gruenberger, Birgit ; Popper, Ulrich ; Prager, Gerald ; Winder, Thomas ; Hendrickx, Koen ; Houbiers, Ghislain ; Lybaert, Willem ; Peeters, Marc ; Van Custem, Eric ; Abdalla, Káthia Cristina ; Campos Bragagnoli, Arinilda ; Carmagani Pestana, Roberto ; Cruz, Felipe José Silva Melo ; Spina Donadio, Mauro Daniel ; Fernandes, Gustavo Dos Santos ; Moniz, Camila Motta Venchiarutti ; Liposits, Gabor Istvan ; Olesen, Rene ; Petersen, Lone Nørgård ; Pfeiffer, Per ; Borg, Christophe ; Boussion, Helene ; Galais, Marie-Pierre ; Poureau, Pierre-Guillaume ; Taieb, Julien ; Tougeron, David ; Heinemann, Volker ; Kisro, Jens ; Modest, Dominik Paul ; Schwaner, Ingo ; Arkosy, Péter ; Bodoky, György ; Csejtei, András ; Csöszi, Tibor ; Horvath, Zsolt ; Nagy, Zoltan ; Olah, Judith ; Pápai, Zsuzsanna ; Sipöcz, István ; Avallone, Antonio ; Banzi, Maria ; Bilancia, Domenico ; Ciardiello, Fortunato ; Cremolini, Chiara ; Lonardi, Sara ; Maiello, Evaristo ; Personeni, Nicola ; Scartozzi, Mario ; Duchnowska, Renata ; Itrych, Bartosz ; Karaszewska, Boguslawa ; Radecka, Barbara ; Rogowski, Wojciech ; Wyrwicz, Lucjan ; Wysocki, Piotr ; Fedyanin, Mikhail ; Kirtbaya, Dmitry ; Kislov, Nikolay ; Kopp, Mikhail ; Lebedeva, Ludmila ; Ledin, Evgeny ; Makarova, Yulia ; Moiseenko, Fedor ; Orlova, Rashida ; Radyukova, Irina ; Semiglazova, Tatiana ; Stroyakovskyi, Daniil ; Tjulandin, Sergei A ; ELEZ FERNANDEZ, MARIA ELENA; Ferreiro-Monteagudo, Reyes ; Grávalos-Castro, Cristina ; Polo-Marqués, Eduardo ; Pachón Olmos, Vanessa ; Ortiz-Morales, María José ; Rivera, Fernando ; Safont, María José ; Soler, Gemma ; TABERNERO CATURLA, JOSEP; Valladares Ayerbes, Manuel ; Virgili Manrique, Anna C ; Bondarekno, Igor ; Kolachko, Iryna ; Krulko, Stepan ; Ostapenko, Yuriy ; Paramonov, Viktor ; Ponomarova, Olga ; Ryspayeva, Dinara ; Shevnia, Serhii ; Shparyk, Yaroslav ; Bekaii-Saab, Tanios S ; Birhiray, Ruemu E ; Burhani, Nafisa ; Cruz-Correa, Marcia ; Cusnir, Mike ; Desai, Pratibha ; Fakih, Marwan G ; Hall, Ryan ; Jin, Zhaohui ; Jones, Jeremy C ; Lu, Jonathan ; Natarajan, Nagendra ; Shahinian, Haroutioun.NEW ENGLAND JOURNAL OF MEDICINE.1.1.158,5. .10.1056/NEJMoa2214963
  31. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR  trial..Subbiah, Vivek ; Kreitman, Robert J ; Wainberg, Zev A ; Gazzah, Anas ; Lassen, Ulrik ; Stein, Alexander ; Wen, Patrick Y ; Dietrich, Sascha ; de Jonge, Maja J A ; Blay, Jean-Yves ; Italiano, Antoine ; Yonemori, Kan ; Cho, Daniel C ; de Vos, Filip Y F L ; Moreau, Philippe ; ELEZ FERNANDEZ, MARIA ELENA; Schellens, Jan H M ; Zielinski, Christoph C ; Redhu, Suman ; Boran, Aislyn ; Passos, Vanessa Q ; Ilankumaran, Palanichamy ; Bang, Yung-Jue.NATURE MEDICINE.1.1.82,9.30.10.1038/s41591-023-02321-8
  32. Seeking therapeutic synergy in BRAF mutant colorectal cancer..ELEZ FERNANDEZ, MARIA ELENA; ROS MONTAÑA, JAVIER; TABERNERO CATURLA, JOSEP.NATURE MEDICINE.1.1.82,9.4.10.1038/s41591-022-02192-5
  33. Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine  tumours 1-2 cm in size: a retrospective, Europe-wide, pooled cohort study..Nesti, Cédric ; Bräutigam, Konstantin ; Benavent, Marta ; Bernal, Laura ; Boharoon, Hessa ; Botling, Johan ; Bouroumeau, Antonin ; Brcic, Iva ; Brunner, Maximilian ; Cadiot, Guillaume ; Camara, Maria ; Christ, Emanuel ; Clerici, Thomas ; Clift, Ashley K ; Clouston, Hamish ; Cobianchi, Lorenzo ; Cwikla, Jaroslaw B ; Daskalakis, Kosmas ; Frilling, Andrea ; Garcia-Carbonero, Rocio ; Grozinsky-Glasberg, Simona ; HERNANDO CUBERO, JORGE; Hervieu, Valérie ; Hofland, Johannes ; Holmager, Pernille ; Inzani, Frediano ; Jann, Henning ; Jimenez-Fonseca, Paula ; Kaçmaz, Enes ; Kaemmerer, Daniel ; Kaltsas, Gregory ; Klimacek, Branislav ; Knigge, Ulrich ; Kolasinska-Cwikla, Agnieszka ; Kolb, Walter ; Kos-Kudla, Beata ; Kunze, Catarina Alisa ; Landolfi, Stefania ; Rosa, Stefano La ; López, Carlos López ; Lorenz, Kerstin ; Matter, Maurice ; Mazal, Peter ; Mestre-Alagarda, Claudia ; Del Burgo, Patricia Morales ; van Dijkum, Els J M Nieveen ; Oleinikov, Kira ; Orci, Lorenzo A ; Panzuto, Francesco ; Pavel, Marianne ; Perrier, Marine ; Reims, Henrik Mikael ; Rindi, Guido ; Rinke, Anja ; Rinzivillo, Maria ; Sagaert, Xavier ; Satiroglu, Ilker ; Selberherr, Andreas ; Siebenhüner, Alexander R ; Tesselaar, Margot E T ; Thalhammer, Michael J ; Thiis-Evensen, Espen ; Toumpanakis, Christos ; Vandamme, Timon ; van den Berg, José G ; Vanoli, Alessandro ; van Velthuysen, Marie-Louise F ; Verslype, Chris ; Vorburger, Stephan A ; Lugli, Alessandro ; Ramage, John ; Zwahlen, Marcel ; Perren, Aurel ; Kaderli, Reto M.LANCET ONCOLOGY.1.1.51,1.18.10.1016/S1470-2045(22)00750-1
  34. SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry.Cortellini, Alessio ; TABERNERO CATURLA, JOSEP; Mukherjee, Uma ; Salazar, Ramon ; Sureda, Anna ; Maluquer, Clara ; Ferrante, Daniela ; Bower, Mark ; Sharkey, Rachel ; MIRALLAS VIÑAS, ORIOL; Plaja, Andrea ; Cucurull, Marc ; Mesia, Ricard ; Dalla Pria, Alessia ; Newsom-Davis, Thomas ; Van Hemelrijck, Mieke ; Sita-Lumsden, Ailsa ; Apthorp, Eleanor ; Vincenzi, Bruno ; Fazio, Giuseppina Rita Di ; Tonini, Giuseppe ; Pantano, Francesco ; Bertuzzi, Alexia ; Rossi, Sabrina ; Brunet, Joan ; Lambertini, Matteo ; Pedrazzoli, Paolo ; Biello, Federica ; D’Avanzo, Francesca ; Lee, Alvin J. X. ; Shawe-Taylor, Marianne ; Rogers, Lucy ; Murphy, Cian ; Cooper, Lee ; Andaleeb, Ramis ; Khalique, Saira ; Bawany, Samira ; Ahmed, Sarah ; Carmona-Garcia, M. Carmen ; Fort-Culillas, Roser ; Linan, Raquel ; Zoratto, Federica ; Rizzo, Gianpiero ; Perachino, Marta ; Doonga, Kris ; Gaidano, Gianluca ; Bruna, Riccardo ; Patriarca, Andrea ; Martinez-Vila, Clara ; Criado, Ignacio Perez ; Giusti, Raffaele ; Mazzoni, Francesca ; Antonuzzo, Lorenzo ; Santoro, Armando ; Parisi, Alessandro ; Queirolo, Paola ; Aujayeb, Avinash ; Rimassa, Lorenza ; Diamantis, Nikolaos ; Bertulli, Rossella ; Fulgenzi, Claudia A. M. ; D’Alessio, Antonio ; Ruiz-Camps, Isabel ; SAOUDI GONZALEZ, NADIA; GARCIA ILLESCAS, DAVID; Medina, Irene ; FOX, M. LAURA; Gennari, Alessandra ; AGUILAR COMPANY, JUAN; Pinato, David J. ; OnCovid Study Grp.LANCET ONCOLOGY.1.1.51,1.9.10.1016/S1470-2045(23)00056-6
  35. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS  wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a  multicentre, open-label, phase 2 study..Strickler, John H ; Cercek, Andrea ; Siena, Salvatore ; André, Thierry ; Ng, Kimmie ; Van Cutsem, Eric ; Wu, Christina ; Paulson, Andrew S ; Hubbard, Joleen M ; Coveler, Andrew L ; Fountzilas, Christos ; Kardosh, Adel ; Kasi, Pashtoon M ; Lenz, Heinz-Josef ; Ciombor, Kristen K ; ELEZ FERNANDEZ, MARIA ELENA; Bajor, David L ; Cremolini, Chiara ; Sanchez, Federico ; Stecher, Michael ; Feng, Wentao ; Bekaii-Saab, Tanios S ; MOUNTAINEER investigators ; Van Cutsem, Eric ; Peeters, Marc ; Van den Evnde, Marc ; André, Thierry ; Borg, Christophe ; Sarabi, Matthieu ; Ghiringhelli, Francois ; Chibaudel, Benoist ; Siena, Salvatore ; Cremolini, Chiara ; Zampino, Maria G ; ELEZ FERNANDEZ, MARIA ELENA; Keranen, Susana R ; Salazar, Ramon ; Alfonso, Pilar ; Strickler, John H ; Cercek, Andrea ; Ng, Kimmie ; Wu, Christina ; Paulson, Andrew S ; Hubbard, Joleen M ; Coveler, Andrew L ; Fountzilas, Christos ; Kardosh, Adel ; Kasi, Pashtoon M ; Lenz, Heinz-Josef ; Ciombor, Kristen K ; Bajor, David L ; Bekaii-Saab, Tanios S ; Gbolahan, Olumide ; Boland, Patrick ; Berg, Daniel ; Sanchez, Federico ; Goggins, Timothy ; Saeed, Anwar ; Burris, Howard ; Bendell, Johanna ; Outlaw, Darryl ; Tafur, Isaac ; Shergill, Ardaman ; Catenacci, Daniel ; Gong, Jun ; Garrido-Laguna, Ignacio ; Finley, Gene ; Weinberg, Benjamin ; Shields, Anthony ; Philip, Philip ; Turk, Anita ; Nguyen, Anthony ; Braiteh, Fadi ; Patel, Vijay ; Harwin, William ; Anderson, Ian ; Kundra, Ajay ; Chen, Christopher ; Ford, James ; Kundranda, Madappa ; Nguyen, Danny ; Ratnam, Suresh ; Richards, Donald ; Nallapareddy, Sujatha ; Beeram, Sridhar ; McKenney, Scott ; Shao, Spencer.LANCET ONCOLOGY.1.1.51,1.22.10.1016/S1470-2045(23)00150-X
  36. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic  colorectal cancer treated with BRAF combinatorial treatments..ROS MONTAÑA, JAVIER; MATITO ARIZA, JUDIT; VILLACAMPA JAVIERRE, GUILLERMO; COMAS NAVARRO, RAQUEL; GARCIA RODRIGUEZ, ARIADNA MARIA; Martini, G ; BARAIBAR ARGOTA, IOSUNE; SAOUDI GONZALEZ, NADIA; SALVA BALLABRERA, FRANCESC; Martin, Á ; Antista, M ; DE ALMEIDA TOLEDO, RODRIGO; Martinelli, E ; Pietrantonio, F ; Boccaccino, A ; Cremolini, C ; DIENSTMANN, RODRIGO; TABERNERO CATURLA, JOSEP; VIVANCOS PRELLEZO, ANA; ELEZ FERNANDEZ, MARIA ELENA.ANNALS OF ONCOLOGY.1.1.50,5.8.10.1016/j.annonc.2023.02.016
  37. ANCHOR CRC: Results From a Single-Arm, Phase II Study of Encorafenib Plus  Binimetinib and Cetuximab in Previously Untreated BRAF(V600E)-Mutant Metastatic  Colorectal Cancer..Van Cutsem, Eric ; Taieb, Julien ; Yaeger, Rona ; Yoshino, Takayuki ; Grothey, Axel ; Maiello, Evaristo ; ELEZ FERNANDEZ, MARIA ELENA; Dekervel, Jeroen ; Ross, Paul ; Ruiz-Casado, Ana ; Graham, Janet ; Kato, Takeshi ; Ruffinelli, Jose C ; André, Thierry ; Carrière Roussel, Edith ; Klauck, Isabelle ; Groc, Mélanie ; Vedovato, Jean-Claude ; TABERNERO CATURLA, JOSEP.JOURNAL OF CLINICAL ONCOLOGY.1.1.45,4.19.10.1200/JCO.22.01693
  38. Early-Stage Breast Cancer Detection in Breast Milk..SAURA MANICH, CRISTINA; ORTIZ VELEZ, CAROLINA; MATITO ARIZA, JUDIT; ARENAS LAHUERTA, ENRIQUE HUERTA; SUÑOL CAMAS, ANNA; Martín, Ágatha ; Córdoba, Octavi ; MARTINEZ SABADELL, A; García-Ruiz, Itziar ; Miranda, Ignacio ; Morales-Comas, Clara ; CARRASCO LOPEZ, ESTELA; VIAPLANA DONATO, CRISTINA; PEG, VICENTE; NUCIFORO, PAOLO GIOVANNI; BAYO PUXAN, NEUS; Gonzalez-Medina, Alberto ; MIQUEL AYMAR, JOSEP MARIA; GOMEZ REY, MARINA; VILLACAMPA JAVIERRE, GUILLERMO; Arévalo, Silvia ; MUR ESPINOSA, ALEX; BALMAÑA GELPI, JUDITH; DIENSTMANN, RODRIGO; ARRIBAS LOPEZ, JOAQUIN VICENTE; TABERNERO CATURLA, JOSEP; VIVANCOS PRELLEZO, ANA; SANSO MARTINEZ, MIRIAM.CANCER DISCOVERY.1.1.29,1.3.10.1158/2159-8290.CD-22-1340
  39. Hypoxia-Inducible Factor 2 Alpha (HIF2a) Inhibitors: Targeting Genetically Driven  Tumor Hypoxia..DE ALMEIDA TOLEDO, RODRIGO; Jimenez, Camilo ; Armaiz-Pena, Gustavo ; ARENILLAS LALLANA, CARLOTA; CAPDEVILA CASTILLON, JAUME; Dahia, Patricia L M.ENDOCRINE REVIEWS.1.1.20,3.9.10.1210/endrev/bnac025
  40. Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine  neoplasms of gastroenteropancreatic and lung origin..CAPDEVILA, J ; HERNANDO CUBERO, JORGE; Teule, A ; Lopez, C ; Garcia-Carbonero, R ; Benavent, M ; Custodio, A ; GARCIA ALVAREZ, ALEJANDRO; Cubillo, A ; Alonso, V ; Carmona-Bayonas, A ; Alonso-Gordoa, T ; Crespo, G ; Jimenez-Fonseca, P ; Blanco, M ; Viudez, A ; La Casta, A ; Sevilla, I ; Segura, A ; Llanos, M ; LANDOLFI, STEFANIA; NUCIFORO, PAOLO GIOVANNI; Manzano, J L.NATURE COMMUNICATIONS.1.1.16,6.2.10.1038/s41467-023-38611-5
  41. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients  with HER2-expressing metastatic colorectal cancer..Yoshino, Takayuki ; Di Bartolomeo, Maria ; Raghav, Kanwal ; Masuishi, Toshiki ; Loupakis, Fotios ; Kawakami, Hisato ; Yamaguchi, Kensei ; Nishina, Tomohiro ; Wainberg, Zev ; ELEZ FERNANDEZ, MARIA ELENA; Rodriguez, Javier ; Fakih, Marwan ; Ciardiello, Fortunato ; Saxena, Kapil ; Kobayashi, Kojiro ; Bako, Emarjola ; Okuda, Yasuyuki ; Meinhardt, Gerold ; Grothey, Axel ; Siena, Salvatore ; DESTINY-CRC01 investigators ; Di Bartolomeo, Maria.NATURE COMMUNICATIONS.1.1.16,6.8.10.1038/s41467-023-38032-4
  42. Long-term platinum-based drug accumulation in cancer-associated fibroblasts  promotes colorectal cancer progression and resistance to therapy..Linares, Jenniffer ; Sallent-Aragay, Anna ; Badia-Ramentol, Jordi ; Recort-Bascuas, Alba ; Méndez, Ana ; Manero-Rupérez, Noemí ; Re, Daniele Lo ; Rivas, Elisa I ; Guiu, Marc ; Zwick, Melissa ; Iglesias, Mar ; Martinez-Ciarpaglini, Carolina ; Tarazona, Noelia ; Varese, Monica ; Hernando-Momblona, Xavier ; Cañellas-Socias, Adrià ; Orrillo, Mayra ; Garrido, Marta ; SAOUDI GONZALEZ, NADIA; ELEZ FERNANDEZ, MARIA ELENA; Navarro, Pilar ; TABERNERO CATURLA, JOSEP; Gomis, Roger R ; Batlle, Eduard ; Pisonero, Jorge ; Cervantes, Andres ; Montagut, Clara ; Calon, Alexandre.NATURE COMMUNICATIONS.1.1.16,6. .10.1038/s41467-023-36334-1
  43. Liquid Biopsy Detects Early Molecular Response and Predicts Benefit to First-Line  Chemotherapy plus Cetuximab in Metastatic Colorectal Cancer: PLATFORM-B Study..Vidal, Joana ; Fernández-Rodríguez, Maria Concepción ; Casadevall, David ; Garcia-Alfonso, Pilar ; Páez, David ; Guix, Marta ; Alonso, Vicente ; Cano, María Teresa ; Santos, Cristina ; Durán, Gema ; ELEZ FERNANDEZ, MARIA ELENA; Manzano, Jose Luis ; Garcia-Carbonero, Rocio ; Ferreiro-Monteagudo, Reyes ; Losa, Ferran ; Pineda, Estela ; Sastre, Javier ; Rivera, Fernando ; Bellosillo, Beatriz ; TABERNERO CATURLA, JOSEP; Aranda, Enrique ; Salazar, Ramon ; Montagut, Clara.CLINICAL CANCER RESEARCH.1.1.11,5.8.10.1158/1078-0432.CCR-22-1696
  44. Association of immune-related adverse events with the outcomes of immune  checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer..Nasca, Vincenzo ; Barretta, Francesco ; Corti, Francesca ; Lonardi, Sara ; Niger, Monica ; ELEZ FERNANDEZ, MARIA ELENA; Fakih, Marwan ; Jayachandran, Priya ; Shah, Aakash Tushar ; Salati, Massimiliano ; Fenocchio, Elisabetta ; Salvatore, Lisa ; Cremolini, Chiara ; ROS MONTAÑA, JAVIER; Ambrosini, Margherita ; Mazzoli, Giacomo ; Intini, Rossana ; Overman, Michael J ; Miceli, Rosalba ; Pietrantonio, Filippo.Journal for ImmunoTherapy of Cancer.1.2.10,9.2.10.1136/jitc-2022-005493
  45. Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year  results of GEMCAD-1402..Pesántez, David ; Ten Hoorn, Sanne ; Machado, Isidro ; García-Albéniz, Xabier ; Rodríguez-Salas, Nuria ; Heredia-Soto, Victoria ; Viñal, David ; Pericay, Carles ; García-Carbonero, Rocio ; Losa, Ferran ; Alonso, Vicente ; Vera, Ruth ; Feliu Batlle, Jaime ; Gallego, Javier ; Salud, Antonieta ; Nogué, Miquel ; Layos, Laura ; Montagut, Clara ; CAPDEVILA CASTILLON, JAUME; Vermeulen, Louis ; Maurel, Joan ; Fernandez-Martos, Carlos.JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE.1.2.10,3. .10.1093/jnci/djad120
  46. Locoregional Failure During and After Short-course Radiotherapy Followed by  Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery:  A 5-Year Follow-up of the RAPIDO Trial..Dijkstra, Esmée A ; Nilsson, Per J ; Hospers, Geke A P ; Bahadoer, Renu R ; Meershoek-Klein Kranenbarg, Elma ; Roodvoets, Annet G H ; Putter, Hein ; Berglund, Åke ; Cervantes, Andrés ; Crolla, Rogier M P H ; Hendriks, Mathijs P ; CAPDEVILA CASTILLON, JAUME; Edhemovic, Ibrahim ; Marijnen, Corrie A M ; van de Velde, Cornelis J H ; Glimelius, Bengt ; van Etten, Boudewijn ; and collaborative investigators.ANNALS OF SURGERY.1.1.10,1.34.10.1097/SLA.0000000000005799
  47. Efficacy of [(177)Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of  different locations: data from the SEPTRALU study..Mitjavila, Mercedes ; Jimenez-Fonseca, Paula ; Belló, Pilar ; Pubul, Virginia ; Percovich, Juan Carlos ; Garcia-Burillo, Amparo ; HERNANDO CUBERO, JORGE; Arbizu, Javier ; Rodeño, Emilia ; Estorch, Montserrat ; Llana, Belén ; Castellón, Maribel ; García-Cañamaque, Lina ; Gajate, Pablo ; Riesco, Maria Carmen ; Miguel, Maria Begoña ; Balaguer-Muñoz, David ; Custodio, Ana ; Cano, Juana María ; Repetto, Alexandra ; Garcia-Alonso, Pilar ; Muros, Maria Angustias ; Vercher-Conejero, Jose Luis ; Carmona-Bayonas, Alberto.EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING.1.1.9,1.5.10.1007/s00259-023-06166-8
  48. Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the  Spanish Registry of Essential Thrombocythemia..Alvarez-Larrán, Alberto ; Cuevas, Beatriz ; Velez, Patricia ; Noya, Soledad ; Caballero-Navarro, Gonzalo ; Ferrer-Marín, Francisca ; Carbonell, Sara ; Pérez-Encinas, Manuel ; Gómez-Casares, María Teresa ; Pérez-López, Raúl ; Magro, Elena ; Moretó, Ana ; Pastor-Galán, Irene ; Angona, Anna ; Mata-Vázquez, María Isabel ; Guerrero-Fernández, Lucía ; Guerra, José María ; Carreño-Tarragona, Gonzalo ; FOX, M. LAURA; Murillo, Ilda ; García-Gutiérrez, Valentín ; Mora, Elvira ; Stuckey, Ruth ; Arellano-Rodrigo, Eduardo ; Hernández-Boluda, Juan Carlos ; Pereira, Arturo.Hemasphere.1.2.9,1. .10.1097/HS9.0000000000000936
  49. Liver transplantation in metastatic colorectal cancer: are we ready for it?.ROS MONTAÑA, JAVIER; SALVA BALLABRERA, FRANCESC; Dopazo, Cristina ; López, Daniel ; SAOUDI GONZALEZ, NADIA; BARAIBAR ARGOTA, IOSUNE; Charco, Ramon ; TABERNERO CATURLA, JOSEP; ELEZ FERNANDEZ, MARIA ELENA.BRITISH JOURNAL OF CANCER.1.2.8,8.3.10.1038/s41416-023-02213-1
  50. DPPA3-HIF1a axis controls colorectal cancer chemoresistance by imposing a slow  cell-cycle phenotype..CUESTA BORRAS, ESTEFANIA; SALVANS GORJON, CANDIDA; ARQUES CASAMITJANA, ORIOL; CHICOTE RAMOS, IRENE; RAMIREZ CORPAS, LORENA; CABELLOS ALONSO, LAIA; MARTINEZ-QUINTANILLA MARTINEZ, JORDI; MUR ESPINOSA, ALEX; GARCIA ALVAREZ, ALEJANDRO; HERNANDO CUBERO, JORGE; Tejedor, Juan Ramón ; MIRALLAS VIÑAS, ORIOL; ELEZ FERNANDEZ, MARIA ELENA; Fraga, Mario F ; TABERNERO CATURLA, JOSEP; NUCIFORO, PAOLO GIOVANNI; CAPDEVILA CASTILLON, JAUME; GARCIA PALMER, HECTOR; PUIG BORREIL, ISABEL.CELL REPORTS.1.2.8,8.0.10.1016/j.celrep.2023.112927
  51. Efficacy and safety of immune checkpoint inhibitors in young adults with  metastatic melanoma..Wong, Selina K ; Blum, Steven M ; Sun, Xiaopeng ; Da Silva, Inês P ; Zubiri, Leyre ; Ye, Fei ; Bai, Kun ; Zhang, Kevin ; Ugurel, Selma ; Zimmer, Lisa ; Livingstone, Elisabeth ; Schadendorf, Dirk ; Serra-Bellver, Patricio ; MUÑOZ COUSELO, EVA; ORTIZ VELEZ, CAROLINA; LOSTES, MARIA JULIA; Huertas, Roberto M ; Arance, Ana ; Pickering, Lisa ; Long, Georgina V ; Carlino, Matteo S ; Buchbinder, Elizabeth I ; Vázquez-Cortés, Leticia ; Jara-Casas, Diego ; Márquez-Rodas, Iván ; González-Espinoza, Iván R ; Balko, Justin M ; Menzies, Alexander M ; Sullivan, Ryan J ; Johnson, Douglas B.EUROPEAN JOURNAL OF CANCER.1.2.8,4.3.10.1016/j.ejca.2022.12.013
  52. Pembrolizumab for previously treated, microsatellite instability-high/mismatch  repair-deficient advanced colorectal cancer: final analysis of KEYNOTE-164..Le, Dung T ; Diaz, Luis A Jr ; Kim, Tae Won ; Van Cutsem, Eric ; Geva, Ravit ; Jäger, Dirk ; Hara, Hiroki ; Burge, Matthew ; O’Neil, Bert H ; Kavan, Petr ; Yoshino, Takayuki ; Guimbaud, Rosine ; Taniguchi, Hiroya ; ELEZ FERNANDEZ, MARIA ELENA; Al-Batran, Salah-Eddin ; Boland, Patrick M ; Cui, Yi ; Leconte, Pierre ; Marinello, Patricia ; André, Thierry.EUROPEAN JOURNAL OF CANCER.1.2.8,4.8.10.1016/j.ejca.2023.02.016
  53. Sex differences on multikinase inhibitors toxicity in patients with advanced  gastroenteropancreatic neuroendocrine tumours..HERNANDO CUBERO, JORGE; ROCA HERRERA, MARIA; GARCIA ALVAREZ, ALEJANDRO; Raymond, Eric ; Ruszniewski, Philippe ; Kulke, Matthew H ; Grande, Enrique ; García-Carbonero, Rocío ; Castellano, Daniel ; Salazar, Ramón ; Ibrahim, Toni ; Teule, Alex ; Alonso, Vicente ; Fazio, Nicola ; Valle, Juan W ; Tafuto, Salvatore ; CARMONA HEREDIA, Mª ANGELES; NAVARRO GARCES, VICTOR; CAPDEVILA CASTILLON, JAUME.EUROPEAN JOURNAL OF CANCER.1.2.8,4.1.10.1016/j.ejca.2023.04.013
  54. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome  post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey..van Doesum, Jaap A ; Salmanton-García, Jon ; Marchesi, Francesco ; Di Blasi, Roberta ; Falces-Romero, Iker ; CABIRTA, ALBA; Farina, Francesca ; Besson, Caroline ; Weinbergerová, Barbora ; Van Praet, Jens ; Schönlein, Martin ; Lopez-Garcia, Alberto ; Lamure, Sylvain ; Guidetti, Anna ; De Ramón-Sánchez, Cristina ; Batinic, Josip ; Gavriilaki, Eleni ; Tragiannidis, Athanasios ; Tisi, Maria Chiara ; Plantefeve, Gaëtan ; Petzer, Verena ; Ormazabal-Velez, Irati ; Marques de Almeida, Joyce ; Marchetti, Monia ; Maertens, Johan A ; Machado, Marina ; Kulasekararaj, Austin G ; Hernández-Rivas, José Ángel ; Gomes da Silva, Maria ; Fernández, Noemí ; Espigado, Ildefonso ; Drgona, Lubos ; Dragonetti, Giulia ; Metafuni, Elisabetta ; Calbacho, Maria ; Blennow, Ola ; Wolf, Dominik ; van Anrooij, Bjorn ; Nunes Rodrigues, Raquel ; Nordlander, Anna ; Martín-González, Juan-Alberto ; Lievin, Raphaël ; JIMENEZ BALAREZO, MARIA MORAIMA DEL CARMEN; Grafe, Stefanie K ; Garcia-Sanz, Ramon ; Córdoba, Raúl ; Rahimli, Laman ; van Meerten, Tom ; Cornely, Oliver A ; Pagano, Livio.Blood Advances.1.2.7,6.7.10.1182/bloodadvances.2022009578
  55. A signature of circulating microRNAs predicts the response to treatment with  FOLFIRI plus aflibercept in metastatic colorectal cancer patients..Toledano-Fonseca, M ; Gómez-España, M A ; ELEZ FERNANDEZ, MARIA ELENA; Grávalos, C ; García-Alfonso, P ; Rodríguez, R ; Losa, F ; Alés Díaz, I ; Graña, B ; Valladares-Ayerbes, M ; García-Ortiz, M V ; Polo, E ; Salgado, M ; Rivera, F ; Safont, M J ; Salud, A ; Ruiz-Casado, A ; TABERNERO CATURLA, JOSEP; Riesco, M C ; Rodríguez-Ariza, A ; Aranda, E ; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD).BIOMEDICINE & PHARMACOTHERAPY.1.1.7,5.2.10.1016/j.biopha.2023.114272
  56. Establishment of patient-derived tumor organoids to functionally inform treatment  decisions in metastatic colorectal cancer..Martini, G ; Belli, V ; Napolitano, S ; Ciaramella, V ; Ciardiello, D ; Belli, A ; Izzo, F ; Avallone, A ; Selvaggi, F ; Menegon Tasselli, F ; Santaniello, W ; Franco, R ; PUIG BORREIL, ISABEL; RAMIREZ CORPAS, LORENA; CHICOTE RAMOS, IRENE; MANCUSO, FRANCESCO MATTIA; CARATU, GINEVRA; Serres, X ; FASANI, ROBERTA; JIMENEZ, JOSE; ROS MONTAÑA, JAVIER; BARAIBAR ARGOTA, IOSUNE; Mulet, N ; Della Corte, C M ; Troiani, T ; VIVANCOS PRELLEZO, ANA; DIENSTMANN, RODRIGO; ELEZ FERNANDEZ, MARIA ELENA; GARCIA PALMER, HECTOR; TABERNERO CATURLA, JOSEP; Martinelli, E ; Ciardiello, F ; ARGILES MARTINEZ, GUILLERMO.ESMO open.1.2.7,3.5.10.1016/j.esmoop.2023.101198
  57. Sex and gender perspectives in colorectal cancer..BARAIBAR ARGOTA, IOSUNE; ROS MONTAÑA, JAVIER; SAOUDI GONZALEZ, NADIA; SALVA BALLABRERA, FRANCESC; GARCIA RODRIGUEZ, ARIADNA MARIA; RODRIGUEZ CASTELLS, MARTA; TABERNERO CATURLA, JOSEP; ELEZ FERNANDEZ, MARIA ELENA.ESMO open.1.2.7,3.9.10.1016/j.esmoop.2023.101204
  58. The value of post-operative chemotherapy after chemoradiotherapy in patients with  high-risk locally advanced rectal cancer-results from the RAPIDO trial..Dijkstra, E A ; Zwart, W H ; Nilsson, P J ; Putter, H ; Roodvoets, A G H ; Meershoek-Klein Kranenbarg, E ; Frödin, J E ; Nygren, P ; Østergaard, L ; Kersten, C ; Verbiené, I ; Cervantes, A ; Hendriks, M P ; CAPDEVILA CASTILLON, JAUME; Edhemovic, I ; van de Velde, C J H ; Marijnen, C A M ; van Etten, B ; Hospers, G A P ; Glimelius, B ; collaborative investigators.ESMO open.1.2.7,3.1.10.1016/j.esmoop.2023.101158
  59. Genomically matched therapy in refractory colorectal cancer according to ESMO  Scale for Clinical Actionability of Molecular Targets: experience of a  comprehensive cancer centre network..Margalef, Núria Mulet ; Castillo, Carmen ; Mosteiro, Miguel ; Pérez, Xavier ; AGUILAR IZQUIERDO, SUSANA; RUIZ PACE, FIORELLA DAFNE; Gil, Marta ; Cuadra, Carmen ; Ruffinelli, José Carlos ; Martínez, Mercedes ; Losa, Ferran ; Soler, Gema ; Teulé, Àlex ; Castany, Roser ; Gallego, Rosa ; Ruíz, Andrea ; GARRALDA CABANAS, ELENA; ELEZ FERNANDEZ, MARIA ELENA; VIVANCOS PRELLEZO, ANA; TABERNERO CATURLA, JOSEP; Salazar, Ramon ; DIENSTMANN, RODRIGO; Santos, Cristina.MOLECULAR ONCOLOGY.1.3.6,6.0.10.1002/1878-0261.13444
  60. Efficacy and safety of pembrolizumab monotherapy in patients with advanced  thyroid cancer in the phase 2 KEYNOTE-158 study..Oh, Do-Youn ; Algazi, Alain ; CAPDEVILA CASTILLON, JAUME; Longo, Federico ; Miller, Wilson Jr ; Chun Bing, Jerry Tan ; Bonilla, Carlos Eduardo ; Chung, Hyun Cheol ; Guren, Tormod K ; Lin, Chia-Chi ; Motola-Kuba, Daniel ; Shah, Manisha ; Hadoux, Julien ; Yao, Lili ; Jin, Fan ; Norwood, Kevin ; Lebellec, Loïc.CANCER.1.3.6,2.4.10.1002/cncr.34657
  61. A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell  vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal  cancer patients; GEMCAD 1602 study..Español-Rego, Marta ; Fernández-Martos, Carlos ; ELEZ FERNANDEZ, MARIA ELENA; Foguet, Carles ; Pedrosa, Leire ; Rodríguez, Nuria ; Ruiz-Casado, Ana ; Pineda, Estela ; Cid, Joan ; Cabezón, Raquel ; Oliveres, Helena ; Lozano, Miquel ; Ginés, Angels ; García-Criado, Angeles ; Ayuso, Juan Ramon ; Pagés, Mario ; Cuatrecasas, Miriam ; Torres, Ferràn ; Thomson, Timothy ; Cascante, Marta ; Benítez-Ribas, Daniel ; Maurel, Joan.CANCER IMMUNOLOGY IMMUNOTHERAPY.1.3.5,8.3.10.1007/s00262-022-03283-5
  62. A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF  V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer..TABERNERO CATURLA, JOSEP; Van Cutsem, Eric ; GARRALDA CABANAS, ELENA; Tai, David ; De Braud, Filippo ; Geva, Ravit ; van Bussel, Mark T J ; Fiorella Dotti, Katia ; Elez, Elena ; de Miguel, María J ; Litwiler, Kevin ; Murphy, Danielle ; Edwards, Michelle ; Morris, Van Karlyle.ONCOLOGIST.1.3.5,8.7.10.1093/oncolo/oyad007
  63. BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR  Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors..Colle, Raphael ; Lonardi, Sara ; Cachanado, Marine ; Overman, Michael J ; ELEZ FERNANDEZ, MARIA ELENA; Fakih, Marwan ; Corti, Francesca ; Jayachandran, Priya ; Svrcek, Magali ; Dardenne, Antoine ; Cervantes, Baptiste ; Duval, Alex ; Cohen, Romain ; Pietrantonio, Filippo ; André, Thierry.ONCOLOGIST.1.3.5,8.5.10.1093/oncolo/oyad082
  64. Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus  Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer..Van Cutsem, Eric ; Yaeger, Rona ; Delord, Jean-Pierre ; TABERNERO CATURLA, JOSEP; Siu, Lillian L ; Ducreux, Michel ; Siena, Salvatore ; ELEZ FERNANDEZ, MARIA ELENA; Kasper, Stefan ; Zander, Thomas ; Steeghs, Neeltje ; Murphy, Danielle ; Edwards, Michelle ; Wainberg, Zev A.ONCOLOGIST.1.3.5,8.0.10.1093/oncolo/oyad210
  65. Pembrolizumab in Asian patients with  microsatellite-instability-high/mismatch-repair-deficient colorectal cancer..Yoshino, Takayuki ; Andre, Thierry ; Kim, Tae Won ; Yong, Wei Peng ; Shiu, Kai-Keen ; Jensen, Benny Vittrup ; Jensen, Lars Henrik ; Punt, Cornelis J A ; Smith, Denis ; Garcia-Carbonero, Rocio ; Alcaide-Garcia, Julia ; Gibbs, Peter ; de la Fouchardiere, Christelle ; Rivera, Fernando ; ELEZ FERNANDEZ, MARIA ELENA; Le, Dung T ; Adachi, Noriaki ; Fogelman, David ; Marinello, Patricia ; Diaz, Luis A Jr.CANCER SCIENCE.2.3.5,7.4.10.1111/cas.15650
  66. Immunotherapy for Colorectal Cancer with High Microsatellite Instability: The  Ongoing Search for Biomarkers..ROS MONTAÑA, JAVIER; BARAIBAR ARGOTA, IOSUNE; SAOUDI GONZALEZ, NADIA; Rodriguez, Marta ; SALVA BALLABRERA, FRANCESC; TABERNERO CATURLA, JOSEP; ELEZ FERNANDEZ, MARIA ELENA.Cancers.2.3.5,2.2.10.3390/cancers15174245
  67. Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution,  and Clinical Implications..SAOUDI GONZALEZ, NADIA; SALVA BALLABRERA, FRANCESC; ROS MONTAÑA, JAVIER; BARAIBAR ARGOTA, IOSUNE; RODRIGUEZ CASTELLS, MARTA; GARCIA RODRIGUEZ, ARIADNA MARIA; Alcaráz, Adriana ; Vega, Sharela ; Bueno, Sergio ; TABERNERO CATURLA, JOSEP; ELEZ FERNANDEZ, MARIA ELENA.Cancers.2.3.5,2.0.10.3390/cancers15164020
  68. Impact of the COVID-19 pandemic in the early-onset colorectal cancer..BARAIBAR ARGOTA, IOSUNE; GARCIA RODRIGUEZ, ARIADNA MARIA; SALVA BALLABRERA, FRANCESC; ROS MONTAÑA, JAVIER; SAOUDI GONZALEZ, NADIA; COMAS NAVARRO, RAQUEL; Castillo, Gloria ; Sanchis, Mireia ; GARCIA ALVAREZ, ALEJANDRO; HERNANDO CUBERO, JORGE; CAPDEVILA CASTILLON, JAUME; Castells, Marta R ; Martí, Marc ; LANDOLFI, STEFANIA; Espín, Eloy ; Navalpotro, Begoña ; Guevara, Jorge ; Dopazo, Cristina ; NUCIFORO, PAOLO GIOVANNI; VIVANCOS PRELLEZO, ANA; TABERNERO CATURLA, JOSEP; ELEZ FERNANDEZ, MARIA ELENA.Translational Oncology.2.4.5.1.10.1016/j.tranon.2023.101668
  69. Managing Metastatic Extrapulmonary Neuroendocrine Carcinoma After First-Line  Treatment..Andreatos, Nikolaos ; McGarrah, Patrick W ; Sonbol, Mohamad Bassam ; Starr, Jason S ; CAPDEVILA CASTILLON, JAUME; Sorbye, Halfdan ; Halfdanarson, Thorvardur R.CURRENT ONCOLOGY REPORTS.2.4.4,7.0.10.1007/s11912-023-01438-w
  70. Use of lenvatinib in the treatment of radioiodine-refractory differentiated  thyroid cancer: a multidisciplinary perspective for daily practice..CAPDEVILA CASTILLON, JAUME; Deandreis, Desiree’ ; Durante, Cosimo ; Leboulleux, Sophie ; Luster, Markus ; Netea-Maier, Romana ; Newbold, Kate ; Singer, Susanne ; Sykiotis, Gerasimos P ; Bartes, Beate ; Farnell, Kate ; Locati, Laura Deborah.European Thyroid Journal.2.3.4,7.0.10.1530/ETJ-23-0068
  71. Advances in immune checkpoint inhibitor combination strategies for microsatellite  stable colorectal cancer..ROS MONTAÑA, JAVIER; Balconi, Francesca ; BARAIBAR ARGOTA, IOSUNE; SAOUDI GONZALEZ, NADIA; SALVA BALLABRERA, FRANCESC; TABERNERO CATURLA, JOSEP; ELEZ FERNANDEZ, MARIA ELENA.Frontiers in oncology.2.4.4,7.9.10.3389/fonc.2023.1112276
  72. Current perspectives on the management of patients with advanced RET-driven  thyroid cancer in Europe..Elisei, Rossella ; Grande, Enrique ; Kreissl, Michael C ; Leboulleux, Sophie ; Puri, Tarun ; Fasnacht, Nicolas ; CAPDEVILA CASTILLON, JAUME.Frontiers in oncology.2.4.4,7.1.10.3389/fonc.2023.1141314
  73. The impact of clinical and translational research on the quality of life during  the metastatic colorectal cancer patient journey..RODRIGUEZ CASTELLS, MARTA; BARAIBAR ARGOTA, IOSUNE; ROS MONTAÑA, JAVIER; SAOUDI GONZALEZ, NADIA; SALVA BALLABRERA, FRANCESC; GARCIA RODRIGUEZ, ARIADNA MARIA; Alcaraz, Adriana ; TABERNERO CATURLA, JOSEP; ELEZ FERNANDEZ, MARIA ELENA.Frontiers in oncology.2.4.4,7.0.10.3389/fonc.2023.1272561
  74. Predictive Impact of RNF43 Mutations in Patients With Proficient Mismatch  Repair/Microsatellite Stable BRAFV600E-Mutated Metastatic Colorectal Cancer  Treated With Target Therapy or Chemotherapy..Moretto, Roberto ; Germani, Marco Maria ; ROS MONTAÑA, JAVIER; Daniel, Francesca ; Ghelardi, Filippo ; Vetere, Guglielmo ; Giordano, Mirella ; DE ALMEIDA TOLEDO, RODRIGO; Bergamo, Francesca ; Randon, Giovanni ; ELEZ FERNANDEZ, MARIA ELENA; Lonardi, Sara ; Pietrantonio, Filippo ; Vignali, Paola ; Rossini, Daniele ; MATITO ARIZA, JUDIT; Ugolini, Clara ; Fontanini, Gabriella ; Masi, Gianluca ; Cremolini, Chiara.Jco Precision Oncology.2.4.4,6. .10.1200/PO.23.00255
  75. COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the  INTENSIVE study..Fazio, Nicola ; Gervaso, Lorenzo ; Halfdanarson, Thorvardur R ; Sonbol, Mohamad ; Eiring, Rachel A ; Pusceddu, Sara ; Prinzi, Natalie ; Lombardi Stocchetti, Benedetta ; Grozinsky-Glasberg, Simona ; Gross, David J ; Walter, Thomas ; Robelin, Patrick ; Lombard-Bohas, Catherine ; Frassoni, Samuele ; Bagnardi, Vincenzo ; Antonuzzo, Lorenzo ; Sparano, Clotilde ; Massironi, Sara ; Gelsomino, Fabio ; Bongiovanni, Alberto ; Ranallo, Nicoletta ; Tafuto, Salvatore ; Rossi, Maura ; Cives, Mauro ; Rasul Kakil, Ibrahim ; Hamid, Hytam ; Chirco, Alessandra ; Squadroni, Michela ; La Salvia, Anna ; HERNANDO CUBERO, JORGE; Hofland, Johannes ; Koumarianou, Anna ; Boselli, Sabrina ; Tamayo, Darina ; Mazzon, Cristina ; Rubino, Manila ; Spada, Francesca.ENDOCRINE-RELATED CANCER.2.5.3,9.0.10.1530/ERC-22-0395
  76. Current professional standing of young medical oncologists in Spain: a nationwide  survey by the Spanish Society of Medical Oncology + MIR section..Martinez, Domingo Antonio Sanchez ; Quilez-Cutillas, Aliica ; Jimenez-Labaig, Pablo ; Sesma, Andrea ; Tarazona, Noelia ; Pacheco-Barcia, Vilma ; Obispo, Berta ; Paez, David ; Quintanar, Teresa ; Sanchez-Canovas, Manuel ; Montes, Ana Fernandez ; FELIP FONT, ENRIQUETA; Rodriguez-Lescure, Alvaro ; ELEZ FERNANDEZ, MARIA ELENA.CLINICAL & TRANSLATIONAL ONCOLOGY.3.6.3,4.1.10.1007/s12094-022-02989-3
  77. Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and  biomarkers..ROS MONTAÑA, JAVIER; RODRIGUEZ CASTELLS, MARTA; SAOUDI GONZALEZ, NADIA; BARAIBAR ARGOTA, IOSUNE; SALVA BALLABRERA, FRANCESC; TABERNERO CATURLA, JOSEP; ELEZ FERNANDEZ, MARIA ELENA.EXPERT REVIEW OF ANTICANCER THERAPY.3.6.3,3.3.10.1080/14737140.2023.2236794
  78. Satisfaction with injection experience of patients with neuroendocrine tumors  enrolled on lanreotide autogel patient support programs: Results from the  international HomeLAN survey..HERNANDO CUBERO, JORGE; Kolarova, Teodora ; Verslype, Chris ; Kaltsas, Gregory ; Houchard, Aude ; Gueguen, Delphine ; De Herder, Wouter W.JOURNAL OF NEUROENDOCRINOLOGY.3.6.3,2.0.10.1111/jne.13281
  79. Expert design thinking workshops to analyze users’ perceived applicability of NUTRI-ONCOCARE algorithm to prevent and treat malnutrition in cancer patients under routine clinical practice conditions in Spain: the ALLIANCE study.Grande, Enrique ; Moreno, Fernando ; Trigo, Jose ; CAPDEVILA CASTILLON, JAUME; Abiles, Jimena ; Sirvent, Mariola ; Garrido-Siles, Margarita ; Olveira, Gabriel ; Ocon, Julia ; Soto, Maria Luisa Fernandez.SUPPORTIVE CARE IN CANCER.1.3.3,1.0.10.1007/s00520-023-08004-x
  80. A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize  immuno-oncology combinations in early-phase trials..HERNANDO CALVO, ALBERTO; VILA CASADESUS, MARIA; Bareche, Yacine ; Gonzalez-Medina, Alberto ; Abbas-Aghababazadeh, Farnoosh ; LO GIACCO, DEBORA GRAZIA; MARTIN CASADO, AGATHA; SAAVEDRA SANTAGADEA, OMAR; BRAÑA GARCIA, IRENE; VIEITO VILLAR, MARIA; FASANI, ROBERTA; Stagg, John ; MANCUSO, FRANCESCO MATTIA; Haibe-Kains, Benjamin ; Han, Ming ; BERCHE BARCELO, ROGER; Pugh, Trevor J ; MIRALLAS VIÑAS, ORIOL; JIMENEZ, JOSE; SAOUDI GONZALEZ, NADIA; VALVERDE MORALES, CLAUDIA M; MUÑOZ COUSELO, EVA; SUAREZ RODRIGUEZ, CRISTINA; DIEZ GARCIA, MARC; ELEZ FERNANDEZ, MARIA ELENA; CAPDEVILA CASTILLON, JAUME; OAKNIN BENZAQUEN, ANA MAZALTOB; SAURA MANICH, CRISTINA; MACARULLA MERCADE, TERESA; CARLES GALCERAN, JOAN; FELIP FONT, ENRIQUETA; DIENSTMANN, RODRIGO; Bedard, Philippe L ; NUCIFORO, PAOLO GIOVANNI; SEOANE SUAREZ, JOAN; TABERNERO CATURLA, JOSEP; GARRALDA CABANAS, ELENA; VIVANCOS PRELLEZO, ANA.Med. . . .0.10.1016/j.medj.2023.07.006
Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.
Privacy Policy
You have read and agreed to our privacy policy
Required